CD335 (NKp46) Monoclonal Antibody (9E2), Functional Grade, eBioscience™, Invitrogen™

Description

• This 9E2 monoclonal antibody reacts with human CD335, which is also known as NKp46
• Expressed on NK cells, CD335 is a member of the natural cytotoxicity receptor family that also includes NKp30 and NKp44
• This type I transmembrane glycoprotein is involved in activating and expanding resting NK cells following interaction with dendritic cells to eliminate tumor and virus-infected (e.g., influenza) cells
• CD335 also interacts with pancreatic beta cells during the development of type I diabetes
• The 9E2 antibody has been reported to induce cytotoxicity
• Applications Reported: This 9E2 antibody has been reported for use in flow cytometric analysis and to induce cytotoxicity in functional assays
• Applications Tested: This 9E2 antibody has been tested by flow cytometric analysis of normal human peripheral blood cells
• This can be used at less than or equal to 0.25 μg per test
• A test is defined as the amount ( μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest
• Storage and handling: Use in a sterile environment
• Filtration: 0.2 μm post-manufacturing filtered
• Purity: Greater than 90%, as determined by SDS-PAGE
• Endotoxin Level: Less than 0.001 ng/ μg antibody, as determined by LAL assay
• Aggregation: Less than 10%, as determined by HPLC
• NKp46 (CD335, NCR1, ) is a cytotoxicity-activating receptor that may contribute to the increased efficiency of activated natural killer (NK) cells to mediate tumor cell lysis
• NKp46 consists of two Ig-like domains assembled to leukocyte immunoglobulin-like (LIR) and killer inhibitory receptors (KIR).